Endophthalmitis Cultures (PROSPER)
Recruitment status was Recruiting
The intent of this surveillance study will be to obtain written permission from patients with bacterial endophthalmitis in order to compare sterilization rates of their cultured bacterial isolates to standard therapy (vancomycin and ceftazidime) versus combination therapy with vancomycin, ceftazidime, and moxifloxacin.
- Cultured bacterial isolates will demonstrate faster in vitro sterilization rates with combination treatment (vancomycin, ceftazidime, and moxifloxacin) compared to "standard therapy" with vancomycin and ceftazidime.
- Longitudinal analysis of resistance patterns of cultured isolates will show increasing rates of multi-antibiotic resistance.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Prospective Surveillance of Patients With Endophthalmitis for Multi-antibiotic Resistance (PROSPER) Study|
|Study Start Date:||October 2011|
|Estimated Study Completion Date:||August 2013|
Adult patients over 18 years of age presenting with endophthalmitis and able to sign consent.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01496794
|Contact: Stephen J Kim, MDfirstname.lastname@example.org|
|United States, Tennessee|
|Vanderbilt Eye Institute||Recruiting|
|Nashville, Tennessee, United States, 37232|
|Contact: Stephen J Kim, MD 615-936-2020 email@example.com|
|Principal Investigator: Stephen J Kim, MD|
|Principal Investigator:||Stephen J Kim, MD||Vanderbilt University|